Sign In
Buy BTAI
$1.26
-0.0400 (-3.08%)
At Close: Jun 23, 2026
8-K: BioXcel Therapeutics, Inc.
03:39am, Wednesday, 13'th May 2020
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange...
BioXcel Therapeutics, Inc. (BTAI) Q1 2020 Earnings Call Transcript
02:31am, Wednesday, 13'th May 2020
Good morning, everyone, and thank you for joining our conference call to discuss BioXcel Therapeutics' financial results and business highlights for the first-quarter 2020. Joining me for the call to
The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter
12:00am, Wednesday, 13'th May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 12)
Acceleron Pharma Inc (NASDAQ...
BioXcel Therapeutics, Inc. (BTAI) CEO Vimal Mehta on Q1 2020 Results - Earnings Call Transcript
07:02pm, Tuesday, 12'th May 2020
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q1 2020 Results Conference Call May 12, 2020 08:30 AM ET Company Participants Vimal Mehta - Founder and CEO Richard Ste
BioXcel Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update
11:00am, Tuesday, 12'th May 2020
Enrollment of the pivotal SERENITY trials is progressing well, with topline data expected in mid-2020 The Company is assessing data for dose escalation in the.
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 11)
Acceleron Pharma Inc (NASDAQ...
BioXcel Therapeutics to Present at the UBS Virtual Global Healthcare Conference
11:00am, Monday, 11'th May 2020
NEW HAVEN, Conn., May 11, 2020 -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial.
Global Pancreatic Cancer Markets, Drugs and Companies 2016-2024 - ResearchAndMarkets.com
12:00am, Monday, 11'th May 2020
The
The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight
12:00am, Sunday, 10'th May 2020
The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB)...
BioXcel Therapeutics to Present at the BofA Securities Virtual Health Care Conference
11:00am, Thursday, 07'th May 2020
NEW HAVEN, Conn., May 07, 2020 -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial.
BioXcel Therapeutics to Host First Quarter 2020 Operating and Financial Results Conference Call and Webcast
11:00am, Tuesday, 05'th May 2020
NEW HAVEN, Conn., May 05, 2020 -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence.
Canaccord Genuity Believes Bioxcel Therapeutics (BTAI) Won't Stop Here
10:10am, Friday, 01'st May 2020
Canaccord Genuity analyst Sumant Kulkarni maintained a Buy rating on Bioxcel Therapeutics (BTAI) today and set a price target of $68.00. The company's
Canaccord Genuity Believes Bioxcel Therapeutics (NASDAQ: BTAI) Won’t Stop Here
10:10am, Friday, 01'st May 2020
Canaccord Genuity analyst
Sumant Kulkarni
maintained a
Buy
rating on Bioxcel Therapeutics (
BTAI
–
Research Report
) today and set a price target of
$68.00
. The company’s shares closed last Thurs
H.C. Wainwright Keeps a Buy Rating on Bioxcel Therapeutics (BTAI)
12:31pm, Tuesday, 28'th Apr 2020
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Bioxcel Therapeutics (BTAI), with a price target of $95.00. The
BioXcel Therapeutics (“BTI” or “Company”) (BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to identify and advance the next wave of medicines in
